INKT Stock — MiNK Therapeutics Inc.: Cash, EV, Pipeline

Share price

$12.05

Market cap

$61.5M

Cash

$8.8M

Enterprise value

$52.7M

Balance sheet

Cash	$8.8M
Debt	$0.0M
Net cash	$8.8M
Enterprise value	$52.7M
Basic shares	5.1M shares
Fully diluted shares	6.1M shares
Fully diluted market cap	$73.2M
Cash per share	$1.73

Cash figures as of 2026-06-30. Database snapshot: 2026-09-21.

Price history

Loading INKT daily closes…

Loading price history…

Upcoming catalysts

Expected	Drug	Phase	Indication	Mgmt guide
Jul 13 - Aug 24	agenT-797	Phase 2	Pneumonia	—

Estimated readout windows: registry primary-completion date + 6-12 weeks. Windows already open are shown from "Now". Drug names link to ClinicalTrials.gov.

Full readout calendar →

Pipeline assets

agenT-797

Phase 2 · Active Modality: allogeneic, off-the-shelf iNKT cell therapy (native)

Target iNKT cells

Partnerships Agenus (iNKT platform patent rights and know-how assigned; field-limited license back); Memorial Sloan Kettering Cancer Center (Phase 2 investigator-sponsored trial, NCT06251973); First Lviv Territorial Medical Union / UNBROKEN Ukraine (Phase 2 pulmonary trial); University of Wisconsin-Madison (Phase 1 investigator-sponsored GvHD prevention trial); NIH/NIAID (STTR grant supporting preclinical and clinical development); Mary Gooze Clinical Trial Award (funds GvHD trial enrollment and operations)

Indications

critical pulmonary immune failure (severe pneumonia with moderate-to-severe hypoxemic acute respiratory failure) (Stage not disclosed)
refractory solid tumor cancers (monotherapy and in combination with anti-PD-1 agents) (Stage not disclosed)
advanced esophageal, gastric, and gastroesophageal junction adenocarcinoma (Phase 2 investigator-sponsored combination with botensilimab and balstilimab) (Stage not disclosed)
graft-versus-host disease prevention in allogeneic HSCT recipients (Phase 1 investigator-sponsored) (Stage not disclosed)
interstitial lung disease and idiopathic pulmonary fibrosis (potential expansion) (Stage not disclosed)

Catalysts

— None
— None

Status note Most advanced product candidate; nearly 100 patients treated across oncology and critical pulmonary immune failure. No lymphodepletion required; activity independent of HLA matching.

MiNK-215

Discovery · Active Modality: CAR-iNKT cell therapy

Target FAP (fibroblast activation protein)

Indications

cancer (not specified) (Stage not disclosed)

Status note Engineered FAP-targeted CAR-iNKT candidate in discovery; part of engineered iNKT pipeline.

MiNK-413

Discovery · Active Modality: CAR-iNKT cell therapy

Target BCMA (B-cell maturation antigen)

Indications

cancer (not specified) (Stage not disclosed)

Status note Engineered BCMA-targeted CAR-iNKT candidate in discovery; part of engineered iNKT pipeline.

Per-asset detail extracted from the 10-Q filed 2026-08-13. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.

Pipeline

Lead drug	agenT-797
Lead indication	Pneumonia
Lead phase	Phase 2
Active trials	1

Active clinical trials

Trial	Phase	Status	Role	Sponsor	BP	Condition(s)	Mgmt guide
NCT07615010	Phase 2	Recruiting	Sponsor	MiNK Therapeutics	—	Pneumonia	—

Sponsor-matched active trials from ClinicalTrials.gov (1 as sponsor, 0 as collaborator); "Sponsor" = company is the lead sponsor, "Collaborator" = company is a collaborator. The BP column flags big-pharma involvement as lead sponsor or collaborator (excluding the company itself). The Mgmt guide column shows what management guided for readout timing when a guided program matches the trial (hover for the quote, click for the source). Trial listings are not a company pipeline slide.

View all 1 active trials for MiNK Therapeutics on ClinicalTrials.gov

No specialist-fund holders in 13F data for this company.

INKT — MiNK Therapeutics Inc.

Balance sheet

Price history

Upcoming catalysts

Pipeline assets

Pipeline

Active clinical trials